

# CRITICAL AND URGENT CARE I PANEL

---

## EDITORIAL BOARD LIAISON

Clarence Chant, Pharm.D., FCCP, FCSHP, BCPS  
*Clinical Pharmacy Specialist*  
Critical Care/Research, Pharmacy Department  
St. Michael's Hospital  
*Assistant Professor*  
Leslie Dan Faculty of Pharmacy  
University of Toronto  
Toronto, Ontario, Canada

Detroit, Michigan  
*Adjunct Assistant Professor*  
Eugene Applebaum College of Pharmacy  
and Health Science  
Wayne State University

Marwan M. Kazimi, M.D.  
*Senior Staff Surgeon*  
Department of Surgery and Transplant Institute  
Henry Ford Health Systems  
Detroit, Michigan

## OBSTETRIC EMERGENCIES IN THE ICU

### Author

Julie J. Kelsey, Pharm.D.  
*Pharmacy Clinical Specialist, Obstetrics and Gynecology*  
Department of Pharmacy Services  
University of Virginia Health System  
Charlottesville, Virginia

### Reviewers

Anne L. Hume, Pharm.D., FCCP, BCPS  
*Professor of Pharmacy*  
Department of Pharmacy Practice  
University of Rhode Island  
Kingston, Rhode Island  
*Adjunct Professor of Family Medicine*  
Alpert School of Medicine at Brown University  
Providence, Rhode Island

### Reviewers

Clarence Chant, Pharm.D., FCCP, BCPS, FCSHP  
*Clinical Pharmacy Specialist*  
Critical Care/Research, Pharmacy Department  
St. Michael's Hospital  
*Assistant Professor*  
Leslie Dan Faculty of Pharmacy  
University of Toronto  
Toronto, Ontario, Canada

Kerri Kraft, Pharm.D., BCPS  
*Clinical Pharmacy Specialist, Solid Organ Transplant*  
Department of Pharmacy  
Kaiser Permanente Colorado  
Aurora, Colorado

Ronald A. Floyd, Pharm.D., M.S., FCCP, BCPS  
*Pharmacy Specialist*  
Department of Pharmacy  
Sharp Mary Birch Hospital for Women and Newborns  
San Diego, California

## MANAGING CARDIOVASCULAR SURGERY INTENSIVE CARE UNIT PATIENTS

### Author

Danielle M. Blais, Pharm.D., BCPS  
*Clinical Assistant Professor*  
*Cardiothoracic Surgery Specialty Pharmacist*  
Department of Pharmacy  
The Ohio State University Medical Center  
Columbus, Ohio

## ICU CONSIDERATIONS AFTER LIVER TRANSPLANT

### Authors

Iman Bajjoka, Pharm.D., FCCP, BCPS  
*Director, Transplant Clinical Research*  
Henry Ford Transplant Institute  
Henry Ford Health System

### Reviewers

Robert J. DiDomenico, Pharm.D.  
*Clinical Associate Professor*  
*Cardiovascular Clinical Pharmacist*  
University of Illinois at Chicago  
University of Illinois Medical Center at Chicago  
Chicago, Illinois

Marianne McCollum, Ph.D., BSPHarm, BCPS  
Assistant Dean for Assessment  
School of Pharmacy  
Rueckert-Hartman College for Health Professions  
Regis University  
Denver, Colorado

Karen M. Whalen, BSPHarm, BCPS  
*Drug Information Pharmacist*  
Department of Pharmacy  
St. Joseph's Hospital  
Syracuse, New York

***The American College of Clinical Pharmacy and the authors thank the following individuals for their careful review of the Book 2, Critical and Urgent Care I chapters:***

Mary C. Gurnee, Pharm.D.  
*Pharmacist Consultant*  
Overland Park, Kansas

Dianne M. Brundage, Pharm.D., FCCP, BCPS, BCOP  
*Oncology Clinical Pharmacy Specialist*  
Park Nicollet Health Services Methodist Hospital  
Minneapolis, Minnesota

# DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

**Consultancies:** Elizabeth Dodds Ashley (Schering-Plough, Merck, Pfizer); Danielle Blais (Facts-Care, The Medicines Company); Robert J. DiDomenico (Scios, The Medicines Company, Sanofi-Aventis, Merck, ARCA Biopharma); Ronald A. Floyd (California Society of Health-System Pharmacists); Anne Julie Frenette (Baxter, Merck Frosst, Eli Lilly); Krystal K. Haase (*Pharmacology Weekly*); Brian A. Hemstreet (Conexus Health); Lisa C. Hutchison (Arkansas Medicaid); Judith Jacobi (Society of Critical Care Medicine, American Board of Applied Toxicology, American Association of Poison Control Centers [spouse or significant other]); Sandra L. Kane-Gill (Baxter, Hospira, Cannon Pharmaceuticals); Steven J. Martin (The Medicines Company, Astellas); Steven Pass (The Medicines Company); John Papadopoulos (Wyeth); Michelle Richardson (Amgen, QualityMetric); Marisel Segarra-Newnham: (Tibotec Therapeutics, USP, *Annals of Pharmacotherapy*); Jeffrey T. Sherer (Sturge-Weber Foundation); Daniel J.G. Thirion (Wyeth, Schering-Plough, Boehringer-Ingelheim [spouse or significant other]); David Williamson (Boehringer-Ingelheim)

**Stock Ownership:** Katherine H. Chessman (Procter & Gamble [stock owned by spouse or significant other]); Ronald A. Floyd (Eli Lilly, Johnson & Johnson, Pfizer); Lisa C. Hutchison (Cardinal Health); Julie J. Kelsey (Pfizer)

**Royalties:** Lisa C. Hutchison (ASHP); Judith Jacobi (Fougera [spouse or significant other]);

**Grants:** Elizabeth Dodds Ashley (Astellas, Schering-Plough [two grants]); Michael L. Bentley (Carilion Clinic, Hospira); Danielle Blais (ASHP); Judy W.M. Cheng (St. Jude's Medical

Research Center); Robert J. DiDomenico (Johnson & Johnson, AHRQ, ACCP Research Institute); Linda Dresser (Palumed [two grants]); Anne Julie Frenette (Aventis Pharma); Brian A. Hemstreet (AstraZeneca); Anne L. Hume (AHRQ [two grants], HRSA); Lisa C. Hutchison (Boehringer-Ingelheim, National Institutes of Health); Judith Jacobi (Luminous Medical, Amgen); Sandra L. Kane-Gill (Ortho McNeil); Scott T. Micek (Astellas Pharma, Ortho-McNeil-Janssen, Xcenda); Asad Patanwala (ASHP Foundation); Michelle Richardson (NIH NIDDK [two grants]); Christine M. Stork (Glaxo); Daniel J.G. Thirion (Wyeth Canada, Pfizer Canada)

**Honoraria:** Elizabeth Dodds Ashley (Merck, Schering-Plough); Danielle Blais (Bayer, Pfizer); Robert J. DiDomenico (Bristol-Myers Squibb, Sanif Pharmaceuticals, Sanofi-Aventis U.S., ACCP, APhA); Sandy J. Estrada (AdvanD, Biomeneux); Steven J. Martin (Ortho-McNeil – PriCara); Scott T. Micek (Merck, Pfizer); Steven Pass (Pfizer); John Papadopoulos (Wyeth, Boehringer-Ingelheim); Michelle Richardson (Amgen); Daniel J.G. Thirion (Wyeth, Merck Frosst); David Williamson (Boehringer-Ingelheim)

**Other:**

**Nothing to Disclose:** Iman E. Bajjoka, Jennifer M. Blanchard, Mitchell Buckley, Mary C. Byrne, Clarence Chant, David M. DiPersio, Wade Flowers, Marwan M. Kazimi, Tyree H. Kiser, Kerri Kraft, Jaelyn M. LeBlanc, Marianne McCollum, Marc M. Perreault, Garrett E. Schramm, Michael C. Thomas, Karen Whalen

**ROLE OF ACCP:** ACCP developed the petition seeking recognition of Pharmacotherapy as a specialty of pharmacy and presented it to the Board of Pharmaceutical Specialties (BPS). As part of its mission to provide leadership, education, advocacy, and resources enabling clinical pharmacists to achieve excellence in practice and research, ACCP also helps pharmacotherapy specialists maintain their certification through PSAP. ACCP reports successful completion of PSAP examinations to BPS for recertification credit. Neither ACCP nor its agents, including the PSAP Editorial Board, authors, reviewers, or other staff, has knowledge of specific examination content, areas of emphasis, or any other information that would compromise the integrity of the examination process.

**ROLE OF BPS:** The Board of Pharmaceutical Specialties is an autonomous certification agency of the American Pharmacists Association. BPS is totally separate and distinct from ACCP. The Board, through its specialty councils, is responsible for specialty examination content, administration, scoring, and all other aspects of its certification programs. PSAP has been approved by BPS for use in BCPS recertification. Information about the BPS recertification process is available at [www.bpsweb.org/recertification/general.cfm](http://www.bpsweb.org/recertification/general.cfm). Other questions regarding recertification should be directed to:

Board of Pharmaceutical Specialties  
2215 Constitution Avenue N.W.  
Washington, DC 20037  
(202) 429-7591  
[www.bpsweb.org](http://www.bpsweb.org)